Amicus Therapeutics, Inc. provided earnings guidance for the full year 2023. For the full-year 2023, the Company expected total revenue growth between 14 and 18% at CER.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.12 USD | +0.85% | +4.71% | -28.72% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.72% | 2.97B | |
+46.19% | 56.65B | |
-6.14% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.33% | 26.75B | |
-21.78% | 19.03B | |
-0.35% | 12.28B | |
+24.18% | 12.26B | |
+28.38% | 12.04B |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.
- Amicus Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2023